Jeong-A Lim

Jeong-A Lim

Auto-generated profile, based on publicly available information

Jeong-A Lim

Division of Medical Genetics, Department of Pediatrics, Duke University Medical Center, Durham, NC, United States

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
AKAditi Korlimarla
Aditi Korlimarla
JLJeong-A Lim
Jeong-A Lim
PMPaul McIntosh
Paul McIntosh
KZKanecia Zimmerman
Kanecia Zimmerman
BSBaodong D. Sun
Baodong D. Sun
PKPriya Kishnani
Priya Kishnani
Background: There are new emerging phenotypes in Pompe disease, and studies on smooth muscle pathology are limited. Gastrointestinal (GI) manifestations are poorly understood and underreported in Pompe disease. Methods: To understand the extent and the effects of enzyme replacement therapy (ERT; alglucosidase alfa) in Pompe disease, we studied the histopathology (entire GI tract) in Pompe mice (GAAKO 6neo/6neo). To determine the disease burden in patients with late-onset Pompe disease (LOPD), we used Patient-Reported Outcomes Measurements Information System (PROMIS)-GI symptom scales and a GI-focused medical history. Results: Pompe mice showed early, extensive, and progressive glycogen accumulation throughout the GI tract. Long-term ERT (6 months) was more effective to clear the glycogen accumulation than short-term ERT (5 weeks). GI manifestations were highly prevalent and severe, presented early in life, and were not fully amenable to ERT in patients with LOPD (n = 58; age range: 18–79 years, median age: 51.55 years; 35 females; 53 on ERT). Conclusion: GI manifestations cause a significant disease burden on adults with LOPD, and should be evaluated during routine clinical visits, using quantitative tools (PROMIS-GI measures). The study also highlights the need for next generation therapies for Pompe disease that target the smooth muscles.

8 December 2022 in JCI Insight
Verified
Journal Article
Open access
PDF file
JLJeong-A Lim
Jeong-A Lim
PKPriya S. Kishnani
Priya S. Kishnani
BSBaodong Sun
Baodong Sun
Glycogen debranching enzyme deficiency in glycogen storage disease type III (GSD III) results in excessive glycogen accumulation in multiple tissues, primarily the liver, heart, and skeletal muscle. We recently reported that an adeno-associated virus vector expressing a bacterial debranching enzyme (pullulanase) driven by the ubiquitous CMV enhancer/chicken β-actin (CB) promoter cleared glycogen in major affected tissues of infant GSD IIIa mice. In this study, we developed a potentially novel dual promoter consisting of a liver-specific promoter (LSP) and the CB promoter for gene therapy in adult GSD IIIa mice. Ten-week treatment with an adeno-associated virus vector containing the LSP-CB dual promoter in adult GSD IIIa mice significantly increased pullulanase expression and reduced glycogen contents in the liver, heart, and skeletal muscle, accompanied by the reversal of liver fibrosis, improved muscle function, and a significant decrease in plasma biomarkers alanine aminotransferase, aspartate aminotransferase, and creatine kinase. Compared with the CB promoter, the dual promoter effectively decreased pullulanase-induced cytotoxic T lymphocyte responses and enabled persistent therapeutic gene expression in adult GSD IIIa mice. Future studies are needed to determine the long-term durability of dual promoter–mediated expression of pullulanase in adult GSD IIIa mice and in large animal models.

1 December 2017 in Molecular Therapy - Methods & Clinical Development
Verified
Journal Article
Open access
JLJeong-A Lim
Jeong-A Lim
Hossein ZareHossein Zare
Hossein Zare
RPRosa Puertollano
Rosa Puertollano
NRNina Raben
Nina Raben

2 January 2026 in EBioMedicine
Verified
Journal Article
Open access
NRNeha Regmi
Neha Regmi
BABijan Abar
Bijan Abar
JLJeong-A Lim
Jeong-A Lim
DKDaniel Kenney-Jung
Daniel Kenney-Jung
MMMichael Malinzak
Michael Malinzak
PKPriya Kishnani
Priya Kishnani
Pompe disease (PD), caused by acid α-glucosidase (GAA) deficiency, leads to glycogen accumulation in various tissues including the central nervous system. While enzyme replacement therapy (ERT) is lifesaving, it does not cross the blood-brain barrier. CNS manifestations including sensorineural hearing loss, dysarthria, and cognitive delay-persist despite ERT. Hence, CNS-specific biomarkers are needed to identify at-risk patients and guide monitoring and treatment. This clinical, retrospective study evaluated the utility of plasma glial fibrillary acidic protein (GFAP) as a potential biomarker of CNS involvement in infantile-onset Pompe disease (IOPD) compared to plasma neurofilament light chain (NfL). Plasma GFAP and NfL levels were measured longitudinally in 37 patients with PD (180 samples, ages 0.1-21 years) and 54 age- and sex-matched controls. Patients were grouped as (1) IOPD with severe neurologic involvement (n = 7), (2) IOPD with attenuated neurologic involvement (n = 13), and (3) late-onset PD without neurologic involvement (LOPD; n = 17). Neurologic status was determined via clinical examination and/or brain MRI white matter grading via Modified Fazekas Scores (MFS). GFAP levels were highest in IOPD patients with severe neurologic involvement. Patients with IOPD in the attenuated neurologic involvement group had, on average, lower plasma GFAP concentrations than those with severe neurologic involvement but greater GFAP levels than patients with LOPD, which resembled controls. GFAP outperformed NfL in differentiating patients with IOPD from controls (AUC = 0.886 vs 0.705) and identifying severe from attenuated neurologic involvement group (AUC = 0.801 vs 0.745). NfL showed high variability between controls and PD subgroups. Plasma GFAP levels reliably reflect CNS disease burden in IOPD and outperform NfL in diagnostic performance. GFAP may be a useful biomarker for detecting and monitoring CNS involvement in PD. Funding was provided in part by Sanofi (Cambridge, Massachusetts, USA). Philanthropic support was provided in part by Judy and Monty Frost, Abigail and JB Spaulding, AG Cox Charity Trust and Macie's Mission.

14 November 2025 in Science Advances
Verified
Journal Article
Open access
RGRebecca A. Gibson
Rebecca A. Gibson
WJWilliam R. Jeck
William R. Jeck
RGRebecca Gould
Rebecca Gould
NJNeha Jumani
Neha Jumani
SCSu Jin Choi
Su Jin Choi
PKPriya Kishnani
Priya Kishnani
Glycogen storage disease (GSD) type IX γ2 is a rare inborn error of metabolism where a defect in glycogenolysis leads to the inability to break down glycogen in the liver. Patients with GSD IX γ2 develop hypoglycemia and advanced liver disease, placing them at risk for liver transplantation. This study evaluates the efficacy of liver-directed AAV gene therapy in a murine model of GSD IX γ2. Phkg2 −/− mice underwent treatment with AAV gene therapy (AAV9-LSP- mPhkg2 , 5 × 10 12 vg/kg, intravenous delivery) at ages 3 or 6 months and were treated for either 2 weeks, 3 months, or 12 months. Results demonstrated that AAV gene therapy reduced GSD IX γ2 disease burden across all primary end points. AAV gene therapy also persisted across the mouse lifespan and reduced preexisting liver fibrosis. This work provides preclinical data supporting AAV gene therapy as a definitive treatment for GSD IX γ2.

1 December 2024 in Annals of Translational Medicine
Verified
Journal Article
Open access
PDF file
RGRebecca Gould
Rebecca Gould
BCBenjamin T. Cocanougher
Benjamin T. Cocanougher
JLJeong-A Lim
Jeong-A Lim
NRNina Raben
Nina Raben
PKPriya Kishnani
Priya Kishnani
Expanding therapeutic options for Pompe disease: a new small molecule inhibitor of glycogen synthase 1 (GYS1) shows preclinical promise in Pompe disease